Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.63 |
| ▸ | FEN1 | P39748 | 2/20 | 0.54 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.54 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.54 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.54 |
| ▸ | ACACB | O00763 | 1/20 | 0.51 |
| ▸ | ACACA | Q13085 | 1/20 | 0.51 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MELK | Q14680 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14936530 | 0.86 | ADORA2B (0.67) | ADORA2BHDAC8HDAC6HDAC1HDAC11 | |
| SCHEMBL14945697 | 0.79 | ADORA2B (0.64) | ADORA2BHDAC8HDAC6HDAC1HDAC11 | |
| SCHEMBL24031225 | 0.78 | HDAC1 (1.00) | ADORA2BHDAC8HDAC6HDAC1HDAC11 | |
| SCHEMBL14944986 | 0.77 | ADORA2B (0.79) | ADORA2BFEN1ERCC5ACACBACACA | |
| SCHEMBL2774054 | 0.76 | HDAC1 (0.60) | ADORA2BHDAC8HDAC6HDAC1HDAC11 | |
| SCHEMBL2776906 | 0.72 | AGTR1 (0.66) | ADORA2BHDAC8HDAC6HDAC1HDAC11 | |
| SCHEMBL7014911 | 0.72 | ERCC1 (0.65) | ADORA2BHDAC8HDAC6HDAC1HDAC11 | |
| SCHEMBL14945651 | 0.72 | ACACB (0.79) | ADORA2BACACBACACA | |
| SCHEMBL21850065 | 0.71 | ADORA2B (0.66) | ADORA2BACACBACACATP53 | |
| SCHEMBL14944950 | 0.71 | ACACB (0.78) | ADORA2BACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | SCHRÖDINGER, INC. | 2020-04-02 | — | — | US | disclosed |
| US-10472374-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2019-01-17 | — | — | US | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ADORA2B 3395/4885HDAC8 959/4885HDAC6 589/4885 |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ADORA2B 3395/4885HDAC8 959/4885HDAC6 589/4885 |
| US-10472374-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | ADORA2B 3395/4885HDAC8 959/4885HDAC6 589/4885 |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ADORA2B 3395/4885HDAC8 959/4885HDAC6 589/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ADORA2B 3395/4885HDAC8 959/4885HDAC6 589/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ADORA2B 3395/4885HDAC8 959/4885HDAC6 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.